Entecavir – new treatment in chronic hepatitis B Waldemar Halota, Małgorzata Pawłowska Medical Science Review - Hepatologia 2006; 6 15-16 aaICID: 449222
Article type: Original article
IC™ Value: 3.59
Abstract provided by Publisher
The authors present pharmacological and clinical data concerning a new nucleoside analog, Entecavir, in the treatment of chronic hepatitis B. In animals and in in vitro studies, entecavir greatly inhibited viral replication, especially in blocking HBV DNA-polimerase priming, reverse transcription of pregenomic mRNA, and HBV DNA synthesis. Entecavir is safe and effective in the treatment of chronic hepatits B in naïve HBeAg-positive and -negative patients as well as in patients with lamivudine resistance.